MTEX on Nasdaq

Mannatech

Logo: Mannatech, Public domain, via Wikimedia Commons4

Multinational multi-level marketing company

Mannatech Inc. is a publicly traded, multinational multi-level marketing firm that sells dietary supplements and personal care products.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1994Founded1

Compare with Niagen Bioscience, Inc., Natural Alternatives International or Cronos Group Inc, or pick any stock.

  • TickerMTEX on Nasdaq1
  • Industryfood industry1
  • HeadquartersFlower Mound1
  • Websitewww.mannatech.com
  • Incorporated inTX5
  • Business address1410 Lakeside Parkway, Suite 200, Flower Mound, Tx 750285
  • Filer categoryNon-accelerated filer, Smaller reporting company5
Mannatech HQ
Photo: Prhartcom, CC BY-SA 4.0, via Wikimedia Commons7

Mannatech Inc. is a publicly traded, multinational multi-level marketing firm that sells dietary supplements and personal care products. It was founded in November 1993 by Samuel Caster, and is headquartered in Flower Mound, Texas. The company's stock is traded on the NASDAQ exchange under the symbol MTEX. As of 2017, Mannatech employed 252 people and sold its products through some 220,000 independent sales associates.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

74.9%Gross margin8
-0.4%Operating margin8
-14.1%Net margin8
-8.3%Revenue growth, 20258
-$4.3MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 98% of the revenue Mannatech broke down this way in fiscal 2025.

  1. Product$106.0M898%down 9% from 2024
  2. Product and Service, Other$1.6M81%up 7% from 2024
  3. Associate Service Fees$400.0K80%down 20% from 2024
Products and services by year
Products and services20242025
Product$115.9M$106.0M
Product and Service, Other$1.5M$1.6M
Associate Service Fees$500.0K$400.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue25¢$27.1M
  • Research and development1¢$800.0K
  • Selling, general and admin37¢$39.7M
  • Other costs26¢$28.2M
  • Income tax11¢$12.3M

Out of $108.0M in revenue.8 The company lost money this year.

Financial statements

Revenue9101112138$108.0M in 2025−32% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $157.7M$157.7M20192020: $151.4M$151.4M2020−4%2021: $159.8M$159.8M2021+6%2022: $137.2M$137.2M2022−14%2023: $132.0M$132.0M2023−4%2024: $117.9M$117.9M2024−11%2025: $108.0M$108.0M2025−8%
Gross profit9101112138$81.0M in 2025−36% since 2019
0$50.0M$100.0M$150.0M2019: $126.2M$126.2M20192020: $115.9M$115.9M2020−8%2021: $125.6M$125.6M2021+8%2022: $104.1M$104.1M2022−17%2023: $102.9M$102.9M2023−1%2024: $91.5M$91.5M2024−11%2025: $81.0M$81.0M2025−11%
Operating income9101112138-$426.0K in 2025
-$5.0M0$5.0M$10.0M2019: $6.4M$6.4M20192020: $4.5M$4.5M2020−30%2021: $9.0M$9.0M2021+101%2022: -$405.0K-$405.0K20222023: -$964.0K-$964.0K2023+138%2024: $1.4M$1.4M20242025: -$426.0K-$426.0K2025
Net income9101112138-$15.2M in 2025
-$20.0M-$10.0M0$10.0M2019: $3.3M$3.3M20192020: $6.3M$6.3M2020+90%2021: $9.8M$9.8M2021+57%2022: -$4.5M-$4.5M20222023: -$2.2M-$2.2M2023−50%2024: $2.5M$2.5M20242025: -$15.2M-$15.2M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Net sales$108.0M$117.9M
Cost of sales$27.1M$26.4M
Gross profit$81.0M$91.5M
Commissions and incentives$41.7M$48.3M
Selling and administrative expenses$39.7M$41.7M
Total operating expenses$81.4M$90.0M
(Loss) income from operations-$426.0K$1.4M
Interest expense, net-$406.0K-$279.0K
Other Nonoperating Income (Expense)-$2.1M$2.6M
(Loss) income before income taxes-$2.9M$3.7M
Income tax expense-$12.3M-$1.2M
Net (loss) income-$15.2M$2.5M
Basic (in dollars per share)-$8.00$1.32
Diluted (in dollars per share)-$8.00$1.32
Basic (in shares)1.9M shares1.9M shares
Diluted (in shares)1.9M shares1.9M shares

Compare Mannatech with another company

The story

Founded by Samuel Caster in 1994.1

Mannatech was founded by Samuel Caster in 1993, as Congress prepared to pass the Dietary Supplement Health and Education Act of 1994, which made feasible the profitable marketing of a wider spectrum of dietary supplements. The company has had a Christian orientation since its founding; the name was intended to evoke manna, and it recruited people to sell its products through its multi-level marketing structure in church congregations. Prior to founding Mannatech, Caster had founded and run Eagle Shield, an insulation manufacturer, and Electracat, a pest control device; both were categorized as a hoax by the Texas Attorney General's office.

Mannatech was founded to sell dietary supplements and personal care products. Before developing its own products, the company sold Manapol, an aloe vera extract made by another company. Its most widely known product has been Ambrotose, a dietary supplement made from sugars derived from plants.

From 1993 to 2009, Rafael Cruz, father of presidential candidate Ted Cruz, was a top salesman for Mannatech.

Mannatech had its initial public offering (IPO) on February 16, 1999, at $8 a share. The stock price settled a few weeks later at a price of $15.13 a share and a market capitalization of $366 million. The IPO raised $12 million in funds to be used for expansion into Australia and the U.K.

False claims and lawsuits

The company came to be known for unproven claims that its products could be used to treat many diseases and conditions, including cancer, diabetes, autism and AIDS. There is no evidence that any of these claims were or are true.

In May 2005 an article was published in Barron's questioning the company's business practices. In September 2005, a class-action lawsuit was filed against Mannatech for alleged violations of the Securities Exchange Act; it was prompted by the Barron's article.

In 2006, Mannatech distributor Vivienne Balonwu, a U.K. general practitioner, was found by the U.K. General Medical Council panel to have "abused her power as a doctor" after it was determined that she had illegally promoted and sold the company's products to people as a treatment for medical conditions such as chronic obstructive pulmonary disease and stroke-related complications. Following patient complaints about her marketing of the products in 2006, Balonwu was dismissed by her employer, Harmoni, a medical services company, and the GMC panel imposed a 15-month penalty period during which she was "to avoid private or short term locum work" and "to complete a supervised personal development plan to tackle shortcomings in her practice".

Also in 2006, Mannatech was named #5 on Forbes’ list of America's 200 Best Small Companies. At the same time, the company came under investigation by the Texas Attorney General in October 2006 for alleged violations of that state's Deceptive Trade Practices Act. In July 2006, Texas Attorney General Greg Abbott formally charged Mannatech, MannaRelief, Sam Caster, and Reginald McDaniel, the company's medical director, with operating an illegal marketing scheme in violation of state law.

Read the full text

A 20/20 undercover investigation that aired June 1, 2007 on ABC Television showed Mannatech's sales associates teaching sales recruits how to target Mannatech products to people with specific illnesses in a manner that purportedly does not violate U.S. federal law, including U.S. Food and Drug Administration regulations, by avoiding direct claims that the products cure any particular diseases.

In August 2007, Caster resigned as CEO of Mannatech. In October 2007, it was reported that the company had fired Grant Thornton LLP as its auditor after the accounting firm demanded that Mannatech remove Caster from all responsibilities to be replaced by Wayne Badovinus as the new chief executive. Several corporate initiatives were undertaken, but after 17 months on the job Badovinus resigned in December 2009. Another member of the board resigned shortly after. Mannatech's Chief Science Officer Robert Sinnott and Mannatech's chief financial officer Steve Fenstermacher were named Co-CEOs. Fenstermacher later resigned.

Publicity over the company's lawsuits began to damage the balance sheets and stock performance. After profits of $32 million in 2006 and $6.6 million in 2007, Mannatech reported a $12.6 million loss in 2008 and a $17.3 million loss in 2009.

Mannatech settled the civil complaint with the State of Texas in February 2009; Mannatech did not admit wrongdoing but agreed to pay $4 million in restitution to clients who purchased products and $2 million to the state to cover its costs in the case. In addition, Sam Caster agreed to pay a $1 million civil penalty and steer clear of any type of leadership position or employment relationship with Mannatech for five years.

In March 2008, Mannatech settled the class-action lawsuit by agreeing to pay $11.25 million to the plaintiff class. As part of the settlement, Mannatech admitted no wrongdoing.

2010 losses were $10.6 million. As the company's market capitalizations continued to fall, S&P Indices dropped it from the S&P 600 Index, stating "They are no longer representative of the small cap market space." Recruiting efforts continued dropping in 2011, widening company losses to $20.6 million. For 2012, the company's net loss narrowed to around $1 million from the about $21 million loss the year before. In 2013, it had around $3 million in net income, and in 2014, it reported profits of $6.5 million and total revenue of $190.1 million.

In November 2017, Mannatech received an FDA warning letter for illegally marketing several of its supplement products as medicinal agents and for selling adulterated and misbranded products in violation of Title 21 of the Code of Federal Regulations and Good Manufacturing Practice regulations for dietary supplements. In December 2017, Mannatech reached an agreement with the Town Council of Flower Mound, Texas, to relocate its headquarters to an existing facility in the city.

Ben Carson

Starting in 2004, neurosurgeon and conservative politician Ben Carson made videos and spoke at company events promoting Mannatech and its products. In 2004, in a speech at a Mannatech event, he credited the company's products with the disappearance of his cancer symptoms.

Carson's image still appeared on the Mannatech's website in 2014, and in the same year he praised their "glyconutrient" supplements in a PBS special (The Missing Link – The Science of Brain Health), sponsored by a group of Mannatech distributors, that was subsequently featured on the site. During the CNBC GOP debate on October 28, 2015, Carson was asked about his relationship with Mannatech and denied any involvement with the company. Politifact rated Carson's denial of any involvement as "false". In November 2015, Mannatech said on its website that, for compliance with Federal campaign finance regulations, the company had removed all references to Carson before he announced his bid for the presidency.

From Wikipedia’s article on Mannatech, shared under CC BY-SA 4.0.6

Leadership

Who has led Mannatech, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (30)

Timeline

  1. Jun 5, 2025New chief executive Landen Granvel Fredrick becomes CEO16
  2. Aug 28, 2015New chief executive Alfredo Bala becomes CEO17
  3. Dec 23, 2009New chief executive Stephen D. Fenstermacher becomes CEO18
  4. Jun 23, 2008New chief executive Wayne Badovinus becomes CEO19
  5. Sep 7, 2007New chief executive Terry L. Persinger becomes CEO20
  6. 1994Founded Founded1

Filings

172 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 54 major events, 71 insider forms, 8 large holders, 19 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Sep 1, 20268-K EDGAR
  3. Aug 19, 2026SCHEDULE 13G/A EDGAR
  4. Aug 19, 2026SCHEDULE 13G/A EDGAR
  5. Aug 12, 20268-K EDGAR
  6. Aug 12, 202610-Q EDGAR
  7. Jun 18, 20264 EDGAR
  8. Jun 18, 20263 EDGAR
  9. Jun 8, 20268-K EDGAR
  10. Jun 5, 20264 EDGAR
  11. Jun 5, 20264 EDGAR
  12. Jun 3, 20268-K EDGAR
  13. May 21, 20264 EDGAR
  14. May 20, 20264 EDGAR
  15. May 20, 20264 EDGAR
  16. May 14, 20268-K EDGAR
  17. May 14, 202610-Q EDGAR
  18. Apr 24, 20268-K EDGAR
  19. Apr 24, 2026SCHEDULE 13D EDGAR
  20. Apr 21, 2026DEFA14A EDGAR

The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 4 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 20, 2026JOBE LARRY ADirectorBuy2,803$4.12$11.5KForm 4
May 19, 2026JOBE LARRY ADirectorBuy5,000$4.20$21.0KForm 4
May 19, 2026Robbins Kevin AndrewDirectorBuy7,100$4.17$29.6KForm 4
Sep 9, 2024JOBE LARRY ADirectorSale16,288$7.75$126.2KForm 4
Sep 9, 2024Rameson TylerDirectorBuy16,288$7.75$126.2KForm 4
May 22, 2024JOBE LARRY ADirectorSale1,012$7.60$7.7KForm 4
Aug 30, 2023BALA ALFREDOCEO and PresidentSale1,000$12.40$12.4KForm 4
Aug 18, 2023JOBE LARRY ADirectorSale1,217$12.82$15.6KForm 4
Jun 30, 2023BALA ALFREDOCEO and PresidentSale115$12.62$1.5KForm 4
Jun 29, 2023BALA ALFREDOCEO and PresidentSale154$12.89$2.0KForm 4
Dec 21, 2022BALA ALFREDOCEO and PresidentSale3,500$19.69$68.9KForm 4
Dec 8, 2022Robbins Kevin AndrewDirectorSale1,500$22.00$33.0KForm 4
Mar 28, 2022Robbins Kevin AndrewDirectorSale1,100$36.57$40.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Terry LacoreSCHEDULE 13G/A, 3 filings Jan 24, 2025 to Aug 19, 202663
  • Robert TothSCHEDULE 13D, 1 filing Apr 24, 202664
  • Marlin Ray RobbinsSC 13G, 1 filing Nov 1, 202465
  • Sudbury Capital Fund, LPSC 13G/A, 2 filings Jan 4, 2022 to Jan 13, 202366
  • Michael ChallenSC 13G/A, 1 filing Feb 8, 202267

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.52,163$271.8K0.0%No change
Vanguard Capital Management LLC41,528$216.4K0.0%−8,089
Renaissance Technologies LLC30,078$156.7K0.0%−800
IFG Advisory, LLC19,090$99.5K0.0%New
Vanguard Fiduciary Trust Co2,679$14.0K0.0%No change
Tower Research Capital LLC (TRC)727$3.8K0.0%+255
Royal Bank Of Canada316$2.0K0.0%+236
Vanguard Global Advisers, LLC250$1.3K0.0%No change
Wells Fargo & Company/mn201$1.0K0.0%+200
UBS Group AG48$2500.0%−437
National Bank Of Canada /fi/30$1500.0%No change
Arax Advisory Partners12$630.0%No change
Acadian Asset Management LLC4,690$240.0%−3,051
Morgan Stanley2$150.0%No change
Citigroup Inc1$50.0%New
SBI Securities Co., Ltd.1$50.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67